Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125653921 | 12565392 | 1 | I | 2016 | 20160714 | 20160718 | 20160718 | EXP | AU-IPSEN BIOPHARMACEUTICALS, INC.-2016-06066 | IPSEN | 81.16 | YR | M | Y | 0.00000 | 20160718 | OT | AU | AU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125653921 | 12565392 | 1 | PS | SOMATULINE AUTOGEL | LANREOTIDE ACETATE | 1 | Subcutaneous | 60 MG | U | L04293/K020064 | 0 | 60 | MG | SOLUTION FOR INJECTION/INFUSION | |||||
| 125653921 | 12565392 | 2 | C | INSULIN | INSULIN NOS | 1 | Subcutaneous | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125653921 | 12565392 | 1 | Carcinoid tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125653921 | 12565392 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125653921 | 12565392 | Decreased appetite | |
| 125653921 | 12565392 | Diarrhoea | |
| 125653921 | 12565392 | Hypoglycaemia | |
| 125653921 | 12565392 | Intestinal obstruction | |
| 125653921 | 12565392 | Skin ulcer | |
| 125653921 | 12565392 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125653921 | 12565392 | 1 | 20160627 | 0 |